Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence

Current Medical Research and Opinion

Volumn 25, Issue 11, 2009, Pages 2765-2775

  Balu, Sanjeev ^a   Simko, Robert J ^a   Quimbo, Ralph M ^b   Cziraky, Mark J ^b  

^a ABBOTT LABORATORIES   (United States)

^b HEALTHCORE INC   (United States)

Author keywords

Adherence; Cardiovascular diseases; Cardiovascular events; Cholesterol; Dyslipidemia; Lipids; Managed care

Indexed keywords

LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; DYSLIPIDEMIA; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; PILL; SEX RATIO;

ADULT; AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COST OF ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HEALTH RESOURCES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TABLETS;

EID: 72549093882     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903297741     Document Type: Article

References (49)

1. Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the national Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003;107:2185-2189
2. Yusuf S, Hawken S, Ounpuu S, et al., for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet 2004;364:937-952
3. Adult Treatment Panel III. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults [final report]. Circulation 2002;106:3143-3421
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
5. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Eng J Med 2007;357:1301-1310 (Pubitemid 47481452)
6. Stanek EJ, Sarawate C, Willey VJ, et al. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 2007;23:553-563 (Pubitemid 46456903)
7. Sarawate CA, Cziraky MJ, Stanek EJ, et al. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed? Clin Ther 2007;29:196-209
8. Windler E, Schoffauer M, Zyriax B-C. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diabetes Vasc Dis Res 2007;4:136-142 (Pubitemid 47167498)
9. Quimbo RA, Simko RJ, Cziraky MJ, et al. Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the US. J Med Econ 2008;11:449-470
10. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151
11. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-443
12. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-779
13. Gehi AK, Ali S, Na B, et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med 2007;167:1798-1803 (Pubitemid 47403069)
14. Gibson TB, Mark TL, Axelsen K, et al. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 2006;12:SP11-19 (Pubitemid 46053391)
15. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Should we target patients with the most to gain? J Gen Intern Med 2004;19:638-645
16. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications. A cross-national study. JAMA 1998;279:1458-1462
17. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-461 (Pubitemid 34787476)
18. Schultz JS, O'Donnell JC, McDonough KL, et al. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005;11:306-312
19. Sung JCY, Nichol MB, Venturini F, et al. factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998;4:1421-1430 (Pubitemid 28506805)
20. Ye X, Gross CR, Schommer J, et al. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 2007;29:2748-2757
21. Batal HA, Krantz MJ, Dale RA, et al. Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res 2007;7:175
22. Peterson AM, McGhan WF. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 2005;23:13-25
23. Patel BV, Remigio-Baker RA, Thiebauld P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008;9:61
24. Legorreta A, Yu A, Chernicoff H, et al. Adherence to combined lamivudine zidovudine versus individual components: a community-based retrospective Medicaid claims analysis. AIDS Care 2005;17:938-948 (Pubitemid 41499307)
25. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-614
26. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-1283 (Pubitemid 47216196)
27. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719 (Pubitemid 47176510)
28. Becker DM, Allen JK. Improving compliance in your dyslipidemia patient: an evidence-based approach. J Am Acad Nurse Pract 2001;13:200-207
29. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831-838
30. Murray MD, Kroenke K. Polypharmacy and medication adherence: small steps on a long road. J Gen Intern Med 2001;16:137-139 (Pubitemid 32183574)
31. Ballentine NH. Polypharmacy in the elderly: maximizing benefit, minimizing harm. Crit Care Nurs Q 2008;31:40-45
32. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004;2:485-501
33. LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form niacin extended-release/lovastatin compared with statin alone or in combination with niacin extended-release. Ann Pharmacother 2006;40:1274-1279 (Pubitemid 44204956)
34. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-457 (Pubitemid 41022729)
35. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veteran Affairs. Am J Med 2007;120:26-32 (Pubitemid 46026987)
36. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725 (Pubitemid 44841979)
37. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
38. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619
39. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-1029
40. Vinker S, Shani M, Baevsky T, et al. Adherence with statins over 8 years in a usual care setting. Am J Manag Care 2008;14:388-392 (Pubitemid 351928444)
41. Natarajan N, Putnam RW, Yip AM, et al. Family practice patients' adherence to statin medications. Can Fam Physician 2007;53:2144-2145 (Pubitemid 351198296)
42. Huser MA, Evans TS, Berger V. Medication adherence trends with statins. Adv Ther 2005;22:163-171
43. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 2008;62:76-87 (Pubitemid 350294021)
44. Doshi JA, Zhu J, Lee BY, et al. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009;119:390-397
45. Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26:2066-2075 (Pubitemid 40353616)
46. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530
47. Stuart BC, Simoni-Wastila L, Zhao L, et al. Increased persistency in medication use by U.S. Medicare beneficiaries with diabetes is associated with lower hospitalization rates and cost savings. Diabetes Care 2009;32:647-649
48. Hepke KL, Martus MT, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004;10:144-151
49. Meyers CD, Carr MC, Park S, et al. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003;139:996-1002 (Pubitemid 37523064)